Lloyd Mitchell Segal Sells 2,650 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 2,650 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $4.79, for a total transaction of $12,693.50. Following the completion of the sale, the chief executive officer now directly owns 89,166 shares in the company, valued at $427,105.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Lloyd Mitchell Segal also recently made the following trade(s):

• On Wednesday, March 27th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The stock was sold at an average price of $4.63, for a total transaction of $12,269.50.

Repare Therapeutics Stock Up 0.9 %

RPTX stock opened at $4.71 on Friday. The firm’s fifty day moving average is $6.30 and its 200 day moving average is $6.59. Repare Therapeutics Inc. has a 52 week low of $3.08 and a 52 week high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The company had revenue of $13.05 million for the quarter, compared to the consensus estimate of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. On average, research analysts forecast that Repare Therapeutics Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of Repare Therapeutics

Several large investors have recently bought and sold shares of RPTX. Barclays PLC purchased a new stake in shares of Repare Therapeutics in the second quarter worth $36,000. Deutsche Bank AG bought a new position in Repare Therapeutics in the fourth quarter valued at about $40,000. UBS Group AG grew its position in Repare Therapeutics by 26.3% during the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after buying an additional 739 shares during the period. Wells Fargo & Company MN grew its position in shares of Repare Therapeutics by 185.8% during the 4th quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after acquiring an additional 1,977 shares during the period. Finally, SRS Capital Advisors Inc. bought a new position in Repare Therapeutics in the 1st quarter worth $49,000. 85.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on RPTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Wednesday, February 21st. Bloom Burton downgraded shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a research note on Tuesday, February 13th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.